MapLight Therapeutics, Inc. (MPLT)
Market Closed
1 Sep, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
13. 31
+0.34
+2.6214%
After Hours
$
+0.68 +5.1089% 13. 99
545.73M Market Cap
- P/E Ratio
- Div Yield
580,614 Volume
- Eps
$ 12.97
Previous Close Investors:
Want to track MPLT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
Maplight Therapeutics NASDAQ: MPLT reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant improvement in Positive and Negative Syndrome Scale, or PANSS, total scores versus placebo at five weeks.
Marketbeat | 1 month ago
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
Seekingalpha | 2 months ago
